Business Context and Reporting Period
This Form 8-K was filed by TherapeuticsMD, Inc. on April 14, 2022, reporting the completion of a significant asset disposition. The Company, incorporated in Nevada and trading on the Nasdaq under the symbol TXMD, finalized the sale of its wholly-owned subsidiary, vitaCare Prescription Services, Inc. ("vitaCare"), to GoodRx, Inc.
Key Financial Metrics and Transaction Details
- Transaction Proceeds: The Company received approximately $150 million in cash from GoodRx, subject to customary adjustments and holdbacks.
- Contingent Consideration: The Company is eligible to receive up to an additional $7 million in earn-out payments based on vitaCare's financial performance through 2023.
- Debt Prepayment: Pursuant to Amendment No. 9 to its Financing Agreement with Sixth Street Specialty Lending, Inc., the Company prepaid $120 million of its outstanding loans using the first tranche of net proceeds from the divestiture.
- Liquidity Impact: The transaction resulted in a net cash inflow of approximately $30 million (after the $120 million debt prepayment), excluding earn-out potential and holdbacks.
Material Changes Versus Prior Period
The primary material change is the removal of vitaCare from the Company's consolidated financial statements effective April 14, 2022. This divestiture alters the Company's revenue streams and asset base. Additionally, the Company's debt obligations were reduced by $120 million immediately upon closing, significantly impacting its leverage profile compared to the pre-transaction period.
Guidance, Outlook, and Risks
The filing does not provide updated forward-looking guidance or management commentary regarding future revenue or earnings projections. The transaction is subject to adjustments as defined in the Stock Purchase Agreement. The earn-out component introduces a contingency dependent on vitaCare's future performance, which is no longer under the Company's control. Unaudited pro forma financial information reflecting the divestiture and debt prepayment is available in Exhibit 99.1 of the filing.
Investor Verification Checklist
- Verify the final adjusted cash proceeds after accounting for any holdbacks or purchase price adjustments.
- Review the specific performance metrics required to trigger the up to $7 million earn-out payment.
- Examine the unaudited pro forma financial statements (Exhibit 99.1) to understand the post-transaction capital structure.
- Confirm the remaining balance of the Financing Agreement with Sixth Street Specialty Lending, Inc. following the $120 million prepayment.